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Abstract
Introduction: As malaria transmission declines, understanding the differential impact of intensified control on
Plasmodium falciparum relative to Plasmodium vivax and identifying key drivers of ongoing transmission is essential
to guide future interventions.
Methods: Three longitudinal child cohorts were conducted in Papua New Guinea before (2006/2007), during (2008)
and after scale-up of control interventions (2013). In each cohort, children aged 1–5 years were actively monitored
for infection and illness. Incidence of malaria episodes, molecular force of blood-stage infections (molFOB) and
population-averaged prevalence of infections were compared across the cohorts to investigate the impact of
intensified control in young children and the key risk factors for malaria infection and illness in 2013.
Results: Between 2006 and 2008, P. falciparum infection prevalence, molFOB, and clinical malaria episodes
reduced by 47%, 59% and 69%, respectively, and a further 49%, 29% and 75% from 2008 to 2013 (prevalence
41.6% to 22.1% to 11.2%; molFOB: 3.4 to 1.4 to 1.0 clones/child/year; clinical episodes incidence rate (IR) 2.6 to 0.8 to IR
0.2 episodes/child/year). P. vivax clinical episodes declined at rates comparable to P. falciparum between 2006, 2008
and 2013 (IR 2.5 to 1.1 to 0.2), while P. vivax molFOB (2006, 9.8; 2008, 12.1) and prevalence (2006, 59.6%; 2008, 65.0%)
remained high in 2008. However, in 2013, P. vivax molFOB (1.2) and prevalence (19.7%) had also substantially declined.
In 2013, 89% of P. falciparum and 93% of P. vivax infections were asymptomatic, 62% and 47%, respectively,
were sub-microscopic. Area of residence was the major determinant of malaria infection and illness.
Conclusion: Intensified vector control and routine case management had a differential impact on rates of P.
falciparum and P. vivax infections but not clinical malaria episodes in young children. This suggests comparable
reductions in new mosquito-derived infections but a delayed impact on P. vivax relapsing infections due to a
previously acquired reservoir of hypnozoites. This demonstrates the need to strengthen implementation of P. vivax
radical cure to maximise impact of control in co-endemic areas. The high heterogeneity of malaria in 2013 highlights
the importance of surveillance and targeted interventions to accelerate towards elimination.
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Background
Intensification of malaria control measures has been
associated with marked reductions in transmission and
infection and illness burden in many endemic areas [1].
In the Americas [1, 2] and some parts of Asia-Pacific
[3, 4], these reductions have been associated with a
marked shift to the predominance of Plasmodium vivax as
the primary source of Plasmodium spp. infections. In paral-
lel, the proportion of low-density, asymptomatic infections
has been observed to increase [5–8] and transmission be-
comes more heterogeneous [9–11].
The reasons underlying these shifts are likely to be
multifactorial. A major factor for the relative increase in
P. vivax is the poor uptake and/or adherence of anti-
hypnozoite therapy [12, 13]. As a result, P. vivax hypno-
zoites are able to cause repeated bouts of blood-stage
parasitaemia and are responsible for up to 80% of all P.
vivax blood-stage infections [14]. Even in low and very
low transmission settings, most P. vivax infections are
asymptomatic [15, 16] and often of very low density [16]
but almost all carry detectable gametocytaemia [6, 17, 18].
These infections are thus not detected and treated by the
health systems and can sustain transmission. P. vivax is
also considered more easily transmissible given the rapid
maturation and thus early presence of its gametocytes [19]
and faster development cycle in its mosquito host [20].
Lastly, it has also been observed that P. vivax-infected
mosquitoes may be younger and more likely to bite early
and outdoors [21, 22]. All of these factors may render P.
vivax transmission less susceptible to vector control and
routine case management interventions.
The highly heterogeneous nature of malaria transmis-
sion across countries, between neighbouring villages and
within the same village has long been recognised [23–25]
and is driven by an interplay of host, vector and environ-
mental factors [23, 26, 27]. As transmission declines, there
is a tendency for malaria infections to become increasingly
clustered in high-risk populations and high-risk areas
[11, 28] and it becomes more important to be able to
identify these clusters since they may be responsible
for sustaining transmission [11]. There is growing evi-
dence that despite achieving overall reductions in malaria
transmission through improved malaria control, infections
and illness burden in many hyperendemic areas remain
unaltered [29–31] and that more targeted interventions
may be necessary for elimination [11].
In the early 2000s, the overall burden of malaria in
Papua New Guinea (PNG) was amongst the highest in
the Asia-Pacific region, albeit with intensity of trans-
mission geographically highly variable across the
country [27, 32, 33]. Plasmodium falciparum and P.
vivax are the two predominant species that account
for most of the burden of malaria infections and ill-
ness in PNG [32, 34].
Beginning in 2004, with the support of Global Fund to
Fight AIDs, Tuberculosis and Malaria, PNG scaled up its
malaria control interventions through scheduled 3-yearly
nationwide distribution of long-lasting insecticide treated
nets (LLINs), introduction of a test-and-treat approach and
a switch to artemether-lumefantrine (AL) as first-line treat-
ment [35, 36]. Subsequent surveys revealed a substantial de-
cline in the overall burden of malaria [6, 33], with the
nationwide infection prevalence by light microscopy (LM)
declining from 11.1% in 2009 to 0.9% in 2014 [33, 37]. En-
tomological studies also revealed a large decline in human
biting rates from 83 bites/person/night to 31 bites/person/
night [37, 38]. As elsewhere, these reductions in PNG have
gone hand-in-hand with an increase in the proportion of
asymptomatic and sub-microscopic infections [6] and a
pronounced heterogeneity of residual transmission [39]. Al-
though the prevalence of PCR-detectable P. vivax infections
in community surveys has not declined to the same extent
as P. falciparum infection [6], the shift towards P. vivax
predominance has not yet been as pronounced as in neigh-
bouring SE Asia- and SW Pacific countries [7].
To better understand the relationship between changing
transmission and the risk profile of malaria infections and
disease, it is vital to gain insight into the impact that control
measures have on the two main species, P. falciparum and
P. vivax. Using three consecutive longitudinal child cohorts
(1–5-year-old children) conducted in the same study area,
prior [40], during [41] and following 5 years of intensifica-
tion (2013 cohort), we investigated the impact of improved
malaria control on the breadth of metrics including clinical
incidence, incidence of newly acquired infections (i.e. the
molecular force of blood-stage infection, molFOB) [42, 43]
and infection prevalence to better understand changing P.
falciparum and P. vivax epidemiology in the context of
rapid reductions in transmission. In order to guide contin-
ued reductions in transmission, we also investigated the key
drivers of infection and illness in young children during the
period of low transmission in 2013.
Methods
Study design and sites
Three longitudinal cohort studies of 1–5-year-old children
were conducted in the same study area in the Ilahita area
of Maprik District, East Sepik Province in 2006, 2008 and
2013. A detailed description of the study area is given else-
where [40]. Briefly, the study area is located in northern
PNG where malaria transmission is considered hyperen-
demic [34, 44] and all human malaria species are endemic
[40, 41, 45, 46]. Health services are provided solely by the
church-run Ilahita Health Centre with inconsistent ser-
vices from a government aid post. The cohorts were con-
ducted at three different time-points before and during
the scale-up of malaria control interventions in the study
area (Fig. 1).
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Cohorts
2006 cohort (pre-intensification)
Children aged 1–3 years were enrolled into the study
and actively followed up for malaria infection and illness
every 8 weeks for a total of 16 months from March 2006
to August 2007 [40, 42, 43]. Passive case detection at Ila-
hita Health Centre was maintained throughout the study
for detection of clinical episodes. All rapid diagnostic
test (RDT) or LM confirmed febrile illness episodes were
treated with AL (Coartem®, Novartis) (if treated by study
staff) or amodiaquine plus sulphadoxine-pyrimethamine
as per the PNG standard treatment for common illnesses
in children [47] (if receiving treatment from a non-study
source). Children with P. vivax episodes were not treated
with primaquine as it had not yet been introduced into
PNG standard treatment guidelines [47]. Full details of
the study methodology are published [40, 42, 43].
2008 cohort (during early intensification)
Children 1–5 years of age were enrolled into this rando-
mised controlled trial in April 2008, a month after the
first population-wide distribution of LLIN into the study
area [41]. Analysis was restricted to the control arm to
allow comparability to the other two observational stud-
ies. Children were actively checked for malaria infection
and illness fortnightly for the first 3 months and monthly
thereafter for another 7 months. All RDT or LM con-
firmed febrile illness episodes were treated with AL
(Coartem®, Novartis) (if treated by study staff) or Amo-
diaquine plus sulphadoxine-pyrimethamine as per the
PNG standard treatment guidelines [47] (if receiving
treatment from a non-study source). Children with P.
vivax episodes were not treated with primaquine as it
had not yet been introduced into PNG standard treat-
ment guidelines [47]. Full details of the study method-
ology are published [41].
2013 cohort (5 years after sustained control)
This cohort was conducted after 5 years of sustained
malaria control in the study area (Fig. 1) A total of 465
children aged 1–5 years at enrolment from 12 villages
(Ilahita 1–7, Kamanokor, Sunuhu 1 and 2, Balanga and
Balif) in Ilahita area were enrolled from July to Septem-
ber, 2013, and followed for 12 months. Of these, 45 chil-
dren were excluded post hoc (11 withdrawals, 26 lost to
follow-up, 8 with erratic attendance), resulting in a final
sample size of 420 children (90% retention rate). All 420
children ranging in age from 0.9–6.4 years during the
study period were included in the analysis investigating
the key drivers of infection and illness in 2013. A subset
(n = 371) aged ≤ 55months were age-matched to earlier
two cohorts to investigate the changing burden of mal-
aria across the intervention time-points.
At enrolment, demographic and clinical data on recent ill-
ness and medications, bednet use and current state of health
were recorded. Axillary temperatures were measured using
an electronic digital thermometer. A 5-ml (ml) venous blood
sample and two blood slides were collected. Haemoglobin
level was measured using a portable HemoCue machine
(HemoCue, Angholm, Sweden). The location of each child’s
residence was recorded using a Garmin eTrex®.
Following enrolment, children were actively followed
up fortnightly for morbidity surveillance and monthly
for blood sampling (250 μl finger prick sample, two
blood slides and haemoglobin measurement). If a child
had a febrile illness at a morbidity surveillance visit, a
finger prick sample of 250 μL blood and 2 blood slides
were collected. RDT for malaria was performed and, if
positive, children were treated with AL (Coartem®,
Novartis) and occasionally AL plus primaquine for RDT
positive P. vivax, as per PNG standard treatment guide-
lines [48]. Over the course of the study, 9 children were
documented as receiving primaquine, suggesting that
Fig. 1 Study and intervention timeline. Legend: The timeline shows the time-points when the three cohorts were conducted in reference to
malaria control interventions that occurred in the study area
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primaquine was inconsistently administered by health
workers. Anaemic children with haemoglobin < 7.5 g/dL
were given an anthelminthic drug (albendazole) and iron
supplementations while other ailments were treated ac-
cording to PNG standard treatment [48].
Plasmodium spp. infections were detected by real-time
quantitative PCR assay (qPCR), as previously described
[40–43, 49] and LM. Briefly, parasite DNA was extracted
from cell pellets (equivalent to 200 μL whole blood)
using a Favorgen 96-well Genomic DNA Extraction Kit
following the manufacturer’s instructions and eluted in
200 μL elution buffer. The presence of P. falciparum, P.
vivax, P. malariae and P. ovale infections were deter-
mined using two multiplex 2-species qPCR assays [49].
Infections with P. falciparum and P. vivax were further
genotyped for Pfmsp2, Pvmsp1F3 and PvMS16 to iden-
tify individual parasite clones. All blood slides positive
by first read and/or by Plasmodium screening qPCR
[50], as well as 10% of the negatives, were independently
examined by a second microscopist. Any discrepancies
between the first and the second reads were then re-read
by a third expert-level microscopist (WHO Level 1 certi-
fied). The final density was calculated by taking the geo-
metric mean of the two concordant reads.
Statistical analysis
Analysis for this paper occurred in two parts and fo-
cussed on the two predominant species, P. falciparum
and P. vivax. In the first part “Analysis of changing bur-
den of malaria infections and illness: 2006 – 2013”, we
aimed to compare the prevalence, molFOB and clinical
incidence across the three cohorts to determine patterns
of decline for P. falciparum relative to P. vivax across
the intervention time-points. In the second part, “Ana-
lysis of key determinants of malaria infection and illness
during the time of low transmission 2013”, the objective
was to explore the full dataset of the 2013 cohort to
identity factors that were key predictors of infection and
illness during the period of low transmission in 2013. In
both analyses, a clinical malaria episode was defined as
history of febrile illness during the preceding 48 h and/
or measured temperature ≥ 37.5 °C in the presence of a
microscopically detectable infection of any density. The
molFOB (number of genetically unique blood-stage infec-
tions) was calculated from the number of new infections
acquired during the intervals between sampling time-
points by counting all new msp2 alleles for P. falciparum
and msp1F3 and MS16 alleles for P. vivax per unit time
that were not present in the preceding intervals.
Analysis of changing burden of malaria infections and
illness: 2006–2013
Data from each cohort were analysed separately due to
the differences in the sampling schedules and the length
of follow-up between the studies. However, to allow dir-
ect comparison, we used the full dataset of the 2006 co-
hort as the baseline while age-matched subsets of the
2008 and 2013 cohorts were used.
The population-averaged prevalence (referred to as
prevalence) of P. falciparum and P. vivax infections in
the three cohorts was estimated using generalised esti-
mating equations (GEE) with a logit link and an ex-
changeable working correlation matrix, to account for
the dependency between observations from the same
child. Robust standard errors were also used to correct
for working correlation matrix misspecification. Inci-
dence rates (IR) for clinical episodes were calculated
from the total number of clinical episodes experienced
by each child over the study period and was modelled
using negative binomial regression for the 2006 and
2013 cohorts and Poisson regression for the 2008 co-
hort. The relative percentage change in the prevalence
and incidence was calculated using the formula: percent-
age change = ((current estimate − previous estimate)/pre-
vious estimate) × 100. Both the frequency of sampling
and duration of blood-stage infections [51] are import-
ant factors influencing the molFOB variable. Due to the
differences in the frequency of sampling in the 2006,
2008 and 2013 cohorts, it was necessary to censor any
sampling time-points that were not available across all
three cohorts in order to be able to directly compare
the molFOB estimate across the cohorts. Incidence of
new clones was defined as the sum of all new clones
over the study period and derived using negative binomial
regression, adjusting for individual time of exposure.
Analysis of key determinants of malaria infection and
illness during the time of low transmission 2013
Risk factors of infection and malaria episode investigated
in 2013 included the child’s age (years), timing of active
detection of infection visits, area of residence, bednet
use in the previous night, history of febrile illness in the
past 2 weeks, presence of febrile illness, which is defined
as the 2-day history of fever ± axillary temperature ≥ 37.
5 °C, and haemoglobin levels.
For all risk factor analyses, both univariable and multi-
variable regression models including all risk factors were
examined. The association between prevalence of infec-
tions at monthly time-points and the risk factors was es-
timated using GEEs with a logit link and exchangeable
working correlation matrix. Incidence of new blood-
stage infections was estimated using GEE with negative
binomial regression and an exchangeable working
correlation matrix. Due to a very low number of clinical
episodes observed in 2013, we used the total number of
clinical episodes for each child across the follow-up
period to assess the association between incidence of
clinical infections and the risk factors. This was
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estimated using negative binomial regression. The risk
factors were summarised across the study period for
each child as follows: age at enrolment, residence (as-
sumed not to vary across follow-up), mean haemoglobin
level and molFOB. Two multivariable models of the inci-
dence of clinical infections, one including all aggregated
risk factors and molFOB (molFOB-adjusted model) and the
other excluding molFOB (base model) were examined.
Due to reduced levels of transmission in 2013, several
villages had few P. falciparum or P. vivax infections de-
tected, no clinical P. falciparum or P. vivax episodes and
very few new blood-stage clones. Therefore, villages
were grouped into 4 areas with geographically similar
characteristics (1 = Ilahita 1, 2, 3, 4, 6 and 7; 2 = Balanga
and Balif; 3 = Kamanokor and Ilahita 5; and 4 = Sunuhu
1 and 2). Due to the universally high bednet use, ana-
lyses of their association with incidence of new blood-
stage infections and clinical episodes did not converge
and bednet use was excluded from both analyses. The
associations are expressed as odds ratio (OR) and inci-
dence rate ratios (IRR) and were considered to be statis-
tically significant if the Wald test p value was below the
nominal level of significance of 0.05.
The analyses were conducted using Stata 12.0 (Stata-
Corp, USA) and R v2.12 (2011) [2006 cohort molFOB
analysis] and v3.4.0 (2017) [2008 cohort analyses] (R
Core Team, R: A language and environment for statis-
tical computing. R Foundation for Statistical Computing,
Vienna, Austria).
Results
Changing burden of malaria infections and illness: 2006–
2013
The prevalence of infection, molFOB and incidence of
clinical malaria were compared across three independent
age-matched child cohorts conducted before (cohort 1,
n = 264) and during (cohort 2, n = 149; cohort 3, n = 371)
the intensification of malaria control activities. The over-
all prevalence of all Plasmodium spp. infections by PCR
was 79.4% (CI95 76.7–81.9%) in 2006, 77.0% (CI95 73.4–
80.3%) in 2008 and 25.6% (CI95 22.5–29.0%) in 2013,
with P. vivax the predominant species across all time-
points.
In 2006, 2 years prior to the scale-up of control activ-
ities in the study area, prevalence of P. falciparum and
P. vivax was 41.6% (CI95 38.4–44.9%) and 59.6% (CI95
56.6–62.4%) by PCR and 24.8% (CI95 21.9–27.6%) and
45.3% (CI95 42.3–48.3%) by LM, respectively (Fig. 2a, b).
Two years later and within several months of the first
population-wide distribution of LLIN by the National
Malaria Control Program, the prevalence of P. falcip-
arum almost halved [PCR 22.1% (CI95 7.7–27.3%); LM
12.8% (CI95 10.0–16.2%)), Fig. 2a, b], with little observed
impact on P. vivax prevalence [PCR 65.0% (CI95 61.4–
68.4%); LM 49.4% (CI95 45.4–53.5%), Fig. 2a, b]. How-
ever, after 5 years of sustained control in the area, the
prevalence of P. vivax had also substantially declined
(PCR 19.6% (CI95 16.9–22.6%); LM 11.4% (CI95 9.5–
13.6%), Fig. 2a, b), and P. falciparum prevalence had
continued to decline further to 11.2% (CI95 9.2–13.0%)
by PCR and 4.5% (CI95 3.5–5.8%) by LM in 2013 (Fig. 2a,
b). Infections due to P. malariae [2006 (7.9%), 2008
(4.1%), 2013 (0.3%)] and P. ovale [2006 (3.5%), 2008
(3.0%), 2013 (0.2%)] were only occasionally detected by
PCR and also declined from 2006 to 2013.
As observed with the prevalence of infections, the inci-
dence of P. falciparum genetically distinct blood-stage
infections substantially declined following the first LLIN
distribution. In contrast, P. vivax molFOB did not change
over the same interval. P. falciparum molFOB decreased
from 3.4 clones/child/year-at-risk (CI95 3.1–3.6) in 2006
to 1.4 clones/child/year-at-risk (CI95 0.9–1.8) in 2008,
which further declined to 1.0 clones/child/year-at-risk
(CI95 0.9–1.2) in 2013 (Fig. 2c). In contrast, P. vivax mol-
FOB was observed to increase from 9.8 clones/child/
year-at-risk (CI95 9.1–10.5) in 2006 to 12.1 clones/child/
year-at-risk (CI95 10.6–13.5) in 2008, before declining to
1.2 clones/child/year-at-risk (CI95 1.0–1.5%) in 2013
(Fig. 2c).
Interestingly, a different pattern was observed for the
incidence of clinical P. vivax episodes (Fig. 2d). In spite
of the persistence of a relatively high P. vivax prevalence
and molFOB following the first LLIN distribution, the in-
cidence of clinical P. vivax declined by 55% in 2008
(2006, 2.46 episodes/child/year-at-risk (CI95 2.27–2.66);
2008, 1.11 episodes/child/year-at-risk (CI95 0.90–1.36)),
before further declining to 0.23 episodes/child/year-at-
risk (CI95 0.13–0.24) in 2013. This corresponded to
an overall reduction of 91% between 2006 and 2013.
The incidence of clinical P. falciparum exhibited a
similar pattern to that of the prevalence and molFOB,
with a continuous decline (2006, 2.56 episodes/child/
year-at-risk (CI95 2.36–2.77); 2008, 0.76 episodes/
child/year-at-risk (CI95 0.57–1.01); 2013, 0.21 epi-
sodes/child/year-at-risk (CI95 0.14–0.28)), correspond-
ing to an overall reduction of 92% between 2006 and
2013 (Fig. 2d).
Key determinants of malaria infection and illness during
the time of low transmission 2013
Demographic characteristics of enrolled participants
Of the 465 children enrolled into the 2013 cohort, data
from 420 were available for analyses (retention rate
90%). These children ranged in age from 0.9 to 6.4 years
(mean 3.3), 53.8% were male and 93% reported sleeping
under a bednet the previous night. On average, the chil-
dren attended 8 out of the 10 [range 1–10] active detec-
tion of infection visits.
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Prevalence of infections during follow-up
Throughout the follow-up period, 47% children had at
least one P. falciparum infection and 48% had at least
one P. vivax infection (detected by PCR). Overall, the av-
eraged prevalence of P. vivax was 19.9% by PCR and
10.8% by LM, while P. falciparum prevalence was 11.0%
by PCR and 4.2% by LM. Sub-microscopic infections
accounted for 64% of P. falciparum and 47% of P. vivax
infections.
The prevalence of PCR-detectable infections varied
markedly across the different areas (Pf: range 4.5–28.8%,
Pv: range 6.0–45.2%; Table 1) with significantly higher
risk of infection observed amongst children living in
Sunuhu 1 and 2 compared to Ilahita 1, 2, 3, 4, 6 and 7
(Pf crude OR 8.49 (CI95 6.14–11.8) p < 0.001, Pv 12.6
(CI95 8.11–19.6) p value < 0.001); Additional file 1).
Whereas the prevalence and the risk of P. falciparum in-
fections also varied significantly over time (range 7.1–
32.2%, p < 0.0001), P. vivax prevalence and risk was more
stable over time (range 17.8–23.2%, p = 0.1777; see
Table 1 and Additional file 1). The risk of both P. falcip-
arum and P. vivax infections was higher in children
experiencing a febrile illness in the last 2 weeks (Pf:
crude OR 2.97 (CI95 1.57–5.63) p = 0.001, Pv 1.68 (CI95
1.06–2.66) p = 0.028), as well as those with an enlarged
spleen (Pf: crude OR 2.25 (CI95 1.23–4.11) p = 0.009, Pv
1.82 (CI95 1.07–3.11) p = 0.028); see Additional file 1).
The prevalence and risk of P. falciparum infections was
also increased in children experiencing a concurrent fe-
brile illness (crude OR 2.28 (CI95 1.66–3.15) p = 0.001),
increased linearly with age (crude OR 1.24 (CI95 1.09–
1.41) p = 0.001) but declined for every 1 g/dL increase in
haemoglobin level (crude OR 0.72 (CI95 0.64–0.80) p <
0.001; Additional file 1). Bednet use was associated with
a reduced prevalence of infections for both species (Pf
crude OR 0.58 (CI95 0.27–1.29) p = 0.182, Pv 0.80 (CI95
0.45–1.40) p = 0.431), but the very low number of non-
users results in insufficient power. Having received
recent antimalarial treatment was associated with a de-
crease in P. vivax (crude OR 0.36 (CI95 0.15–0.85) p =
0.021; Additional file 1) prevalence and risk.
In multivariate analyses, area of residence, time of visit,
age, haemoglobin level and the presence of a concurrent
febrile illness remained independently associated with the
Fig. 2 Changing burden of malaria infections and illness across the different time-points of malaria control intensification in the study area.
Legend: Impact of improved malaria control on prevalence of infections detectable by a polymerase chain reaction assay (PCR), b light
microscopy (LM), c incidence of new blood-stage infections (molFOB) and d incidence of clinical malaria episodes. Error bars are 95%
confidence intervals
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presence of a P. falciparum infection (Table 1). Area of resi-
dence, time of visit, recent antimalarial use, age and having
an episode of febrile illness in the previous 2 weeks were all
associated with the risk of carrying a P. vivax infection
(Table 1). Risk factors of LM-detectable infections were
similar (see Additional file 2).
Molecular force of blood-stage infections in monthly
intervals
Incidence of new blood-stage infections was determined
for a total of 303.4 person-years of follow-up with each
child at risk of acquiring new blood-stage infections for
an average of 0.73 years during the cohort. The mean
Table 1 Key predictors of infections due to P. falciparum and P. vivax as detected by qPCR in 2013
P. falciparum P. vivax
Observed positive
(%; n = 4363)
OR CI95 p Observed positive
(%; n = 4363)
OR CI95 p
Areas of residence
Ilahita 1–4, 6, 7 4.5 Reference group 6.1 Reference group
Balanga and Balif 4.6 1.01 0.59–1.72 0.969 6.0 0.98 0.51–1.88 0.946
Kamanokor and Ilahita 5 12.9 2.29 1.38–3.80 0.001 38.0 9.22 5.55–15.3 < 0.001
Sunuhu 1 and 2 28.8 7.63 5.34–10.9 < 0.001 45.2 13.7 8.81–21.3 < 0.001
p < 0.0001a p < 0.0001a
Age
Linear 2.91 1.26–6.70 0.012 1.32 1.16–1.51 < 0.001
Quadratic 0.88 0.78–0.99 0.032
ADI visit
Enrolment 18.4 Reference group 23.2 Reference group
Week 4 8.7 0.40 0.27–0.58 < 0.001 21.4 0.80 0.61–1.05 0.105
Week 8 8.7 0.39 0.19–0.46 < 0.001 21.3 0.85 0.65–1.11 0.238
Week 12 7.1 0.30 0.19–0.46 < 0.001 19.1 0.71 0.53–0.96 0.024
Week 16 8.1 0.34 0.22–0.53 < 0.001 17.8 0.65 0.49–0.88 0.004
Week 20 9.9 0.47 0.27–0.79 0.004 20.3 0.66 0.45–0.98 0.04
Week 24 7.6 0.31 0.19–0.52 < 0.001 21.8 0.83 0.59–1.19 0.312
Week 28 7.2 0.36 0.22–0.60 < 0.001 17.9 0.64 0.43–0.94 0.024
Week 32 8.8 0.40 0.25–0.65 < 0.001 18.1 0.57 0.40–0.83 0.004
Week 36 10.8 0.55 0.35–0.85 0.007 18.0 0.53 0.37–0.76 0.001
Week 40 32.2 3.20 2.15–4.74 < 0.001 22.9 0.82 0.56–1.19 0.298
p < 0.0001a p = 0.0129a
Haemoglobin 0.65 0.57–0.74 < 0.001
Recent antimalarial
No 11.5 20.3
Yes 21.3 15.0 0.34 0.17–0.71 0.004
Enlarged spleen
No 10.8 19.2
Yes 38.6 54.6 1.66 0.98–2.79 0.059
Febrile illness
No 10.9 19.7
Yes 25.0 1.84 1.30–2.62 0.001 29.2
b2 weeks history of febrile illness
No 11.5 20.0
Yes 28.6 2.24 0.93–5.38 0.073 38.1 1.84 1.02–3.32 0.042
Multivariate GEE model-based estimates of risk of infection detected at each monthly active case detection visit time-point via backward selection of significant
risk factors. OR multivariate adjusted odds ratio, CI95 95% confidence interval, p p value, ADI active detection of infection.
aOverall significance level for the
variable estimated using Wald chi-square test. bExcluding febrile illness at the time of visit
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molFOB for P. falciparum was 1.6 (CI95 1.4–1.9) new in-
fections per child per year-at-risk and 2.2 (CI95 1.9–2.6)
infections/child/year-at-risk for P. vivax.
The rate of acquiring new P. falciparum clones was
higher in Sunuhu 1 and 2 compared to Ilahita 1, 2, 3, 4,
6 and 7 (Pf IRR 3.10 (CI95 2.08–4.63) p value < 0.001)
and also in those with recent antimalarial use (IRR 10.4
(CI95 5.92–18.2) p value < 0.001, Table 2). Age was not
associated with P. falciparum molFOB in multivariate
analysis despite the significant linear association ob-
served in the crude analysis. The P. vivax molFOB was
increased in both Sunuhu 1 and 2 and Kamanokor and
Ilahita 5 compared to Ilahita 1, 2, 3, 4, 6 and 7 (IRR
8.16 (CI95 5.38–12.4) p value < 0.001 and 6.66 (CI95
4.24–10.5) p value < 0.001, respectively), and also in-
creased linearly with age (IRR 1.26 (CI95 1.13–1.40)
p value < 0.001, Table 2). Both P. falciparum and P.
vivax incidence varied markedly over the follow-up
time period (both p < 0.0001, Table 2).
Predictors of clinical malaria episodes
Over the 10months of follow-up, a total of 366 febrile
illness episodes were observed, of which 109 (30%) were
associated with microscopically confirmed infections (IR,
0.36/child/year), with 51 P. vivax (any density: IR, 0.19)
and 49 P. falciparum (any density: IR, 0.18) episodes.
Another 7 were P. falciparum and P. vivax mixed infec-
tions (any density: IR 0.02), 2 were P. malariae (any
density: IR, 0.07). Clinical episodes with high-density
parasitaemia (≥ 2500 for P. falciparum and ≥ 500 for
non-falciparum infections) accounted for 63.3% (35 Pf,
Table 2 Multivariate predictors of molecularly determined new P. falciparum and P. vivax blood-stage infections in 2013
P. falciparum P. vivax
IR IRR CI95 p IR IRR CI95 p
Areas of residence
Ilahita 1–4, 6,7 1.09 Reference group 0.65 Reference group
Balanga and Balif 1.25 1.22 0.70–2.12 0.485 0.94 1.46 0.81–2.64 0.213
Kamanokor and Ilahita 5 1.82 1.61 0.92–2.80 0.096 4.83 6.66 4.24–10.5 < 0.001
Sunuhu 1 and 2 3.57 3.10 2.08–4.63 < 0.001 5.37 8.16 5.38–12.4 < 0.001
p < 0.0001a p < 0.0001a
Age 1.26 1.13–1.40 < 0.001
ADI visit interval
Enrolment–week 4 1.23 Reference group 3.20 Reference group
Week 4–week 8 0.85 0.58 0.27–1.23 0.153 2.62 0.71 0.52–0.98 0.035
Week 8–week 12 0.22 0.15 0.06–0.38 < 0.001 1.60 0.44 0.30–0.63 < 0.001
Week 12–week 16 0.77 0.50 0.23–1.09 0.081 2.30 0.59 0.43–0.82 < 0.001
Week 16–week 20 1.23 3.20 0.87 0.60–1.25 0.446
Week 20–week 24 2.58 1.99 1.00–3.96 0.049 3.60
Week 24–week 28 1.17 0.83 0.43–1.61 0.583 2.20 0.57 0.41–0.79 < 0.001
Week 28–week 32 1.13 0.84 0.43–1.64 0.602 1.98 0.48 0.34–0.69 < 0.001
Week 32–week 36 1.28 0.89 0.49–1.64 0.719 2.46 0.58 0.42–0.80 < 0.001
Week 36–week 40 7.19 5.55 3.33–9.25 < 0.001 2.26 0.56 0.39–0.79 < 0.001
p < 0.0001a p < 0.0001a
Recent antimalarial useb 8.50 10.4 5.92–18.2 < 0.001 2.79
Febrile illness 2.05 3.02
2 weeks history of febrile illnessc 2.11 2.31
Haemoglobin
≥ 10 g/dL 1.60 2.15
9–9.9 g/dL 1.88 2.48
≤ 9 g/dL 2.06 2.87
Estimates from a multivariate negative binomial regression with GEE model predicting risk of acquiring new species-specific clones for P. falciparum and P. vivax in
a 4-week interval when the child was considered at risk. A backward selection approach was used with the best fitting model consisting of the significant
associations. IR incidence rate, IRR incidence rate ratio, CI95 95% confidence interval, p p value, g/dL grams/decilitre, ADI active detection of infections.
aOverall
significance level for the variable estimated using Wald chi-square test. bAntimalarial treatment within 28 days before the start of the interval. cExcluding febrile
illness at the time of visit
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27 Pv, 7 PfPv mixed) of all the clinical episodes. There
were no P. ovale clinical episodes observed.
The incidence of clinical P. falciparum episodes was
significantly higher in Kamanokor, Ilahita 5 and Sunuhu
1/2 compared to Ilahita 1, 2, 3, 4, 6 and 7 (IRR 4.30
(CI95 1.59–11.6) p value 0.004 and 8.15 (CI95 3.40–19.6)
p value < 0.001, respectively; Table 3). Each 1 g/dL in-
crease in haemoglobin was associated with a 48% reduc-
tion in the incidence of clinical P. falciparum (CI95 0.35–
0.77, p value: 0.001, Table 3), and each 1-year increase in
age was associated with a 38% increase in the rate of clin-
ical P. falciparum (CI95 1.10–1.73, p value: 0.006, Table 3).
After adjustment for molFOB, all remained associated with
the rate of clinical P. falciparum episodes, and a unit in-
crease in molFOB (i.e. one new P. falciparum infection per
child per year-at-risk) was associated with a 10% (CI95
1.02–1.18, p value 0.008) increase in the rate of clinical P.
falciparum infections (Table 3).
The rate of clinical P. vivax episodes was also signifi-
cantly higher in Kamanokor, Ilahita 5 and Sunuhu 1/2
compared to Ilahita 1, 2, 3, 4, 6 and 7 (IRR 8.01 (CI95
3.23–19.9) p value < 0.001 and 3.71 (CI95 1.53–8.99) p
value 0.004, respectively; Table 3). Each 1 g/dL increase
in haemoglobin was associated with a 69% reduction in
the rate of clinical P. vivax (CI95 0.19–0.48, p value <
0.001). After adjustment for molFOB, only area of resi-
dence and haemoglobin remained associated with the
rate of clinical P. vivax episodes (Table 3). A unit in-
crease in molFOB (i.e. one new P. vivax infection per
child per year-at-risk) was associated with a 17% (CI95
1.09–1.25, p value < 0.001) increase in the rate of clinical
P. vivax infections. Age was not associated with the rate
of clinical P. vivax episodes, either before or after adjust-
ment for molFOB.
Discussion
This is the first study in a P. falciparum/P. vivax co-
endemic area and amongst very few studies globally [52]
to examine the impact of improved malaria control on
the epidemiology of malaria in young children using longi-
tudinal cohorts rather than the widely used nationwide
and community household surveys and routine health in-
formation systems [6, 33, 37]. Longitudinal cohort studies
allow for a detailed investigation into the dynamics of in-
fection, and illness, as well as the rate of acquiring new in-
fections (molFOB) and clinical illness over time.
By analysing these metrics in three consecutive longi-
tudinal cohorts in young PNG children, we demonstrate
a differential impact of control interventions on P. vivax
compared to P. falciparum that may be overlooked in
routine surveillance. Following the first LLIN distribu-
tion, the prevalence of P. falciparum infection and both
P. falciparum and P. vivax clinical episodes declined im-
mediately and continuously across the time period of the
three cohorts. Contrastingly, the prevalence and force of
P. vivax blood-stage infections did not decline, remaining
initially relatively high with a substantial decline only evi-
dent in the most recent cohort that was conducted 5 years
after commencement of intensified control in the area.
These observations confirm that key biological differences
between the two species render them differentially suscep-
tible to standard control tools such as LLINs and case
management, highlighting the need for P. vivax-focused
interventions in co-endemic regions.
Notably, the relationship between transmission and
molFOB differs for P. falciparum and P. vivax. P. falcip-
arum metrics are directly linked to blood-stage infec-
tions, which are always mosquito-derived, hence closely
reflecting current levels of transmission. The reductions
Table 3 Key predictors of clinical malaria episodes due to P. falciparum and P. vivax in 2013
P. falciparum P. vivax
Base model molFOB adjusted Base model molFOB adjusted
IR IRR (CI95) p IRR (CI95) p IR IRR (CI95) p IRR (CI95) p
Areas of residence
Ilahita 1–4, 6, 7 0.05 Reference group 0.06 Reference group
Balanga & Balif 0.03 0.63 (0.13–3.14) 0.575 0.56 (0.11–2.81) 0.485 0.06 1.15 (0.32–4.06) 0.833 1.08 (0.30–3.91) 0.909
Kamanokor & Ilahita 5 0.25 4.30 (1.59–11.6) 0.004 3.96 (1.46–10.8) 0.007 0.52 8.01 (3.23–19.9) < 0.001 3.86 (1.44–10.3) 0.007
Sunuhu 1&2 0.50 8.15 (3.40–19.6) < 0.001 6.48 (2.65–15.8) < 0.001 0.33 3.71 (1.53–8.99) 0.004 2.00 (0.77–5.17) 0.152
p < 0.0001a p < 0.0001a p < 0.0001a p < 0.0234a
Age 1.38 (1.10–1.73) 0.006 1.30 (1.03–1.64) 0.026
Haemoglobin 0.52 (0.35–0.77) 0.001 0.61 (0.40–0.92) 0.017 0.31 (0.19–0.48) < 0.001 0.38 (0.24–0.59) < 0.001
FOBb 1.10 (1.02–1.18) 0.008 1.17 (1.09–1.25) < 0.001
Multivariate negative binomial regression model-based estimates predicting risk of clinical P. falciparum and P. vivax. Backward selection approach was used to
derive significant associations. Base models included all variables except molFOB. Incidence is based on aggregated clinical data for entire 10-month study period
thus precluding analysis of recent antimalarial treatment as a covariate. Bednet use was not analysed due to non-converge of data when included into models.
aOverall significance level for the variable estimated using wald chi-square test; molFOB: molecular force of blood-stage infections;
b
molFOB was included as a rate;
IR: Incidence rate; IRR: Incidence rate ratio. CI95 95% confidence interval; p p value
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in P. falciparum molFOB observed across these three co-
horts confirm reductions in P. falciparum prevalence
and EIR observed through monitoring and evaluation of
the national programme [37, 38]. Due to the biological
ability of P. vivax to remain dormant in liver cells as
hypnozoites and to serve as a continuing source of re-
lapsing infections, P. vivax metrics are not able to
differentiate between mosquito-derived and relapsing in-
fections and therefore do not reflect active transmission
as closely as P. falciparum metrics. This is particularly
relevant in PNG, where P. vivax is the predominant spe-
cies detectable in young children and relapses account
for more than 50–80% of P. vivax infections in pre-
school and primary school children [14, 41]. As a conse-
quence, the P. vivax molFOB is a composite measure
reflecting the joint burden of new, mosquito-derived and
relapsing infections [42, 43]. This metric therefore re-
veals a high burden of persisting low-density relapsing
infections in young children, contrasting results of na-
tionwide surveys that showed a comparable decline in
P. falciparum and P. vivax prevalence detectable by
LM in both children under 5 years and the general
population [37].
Given the persistence of a high burden of P. vivax in-
fections following the initial LLIN distribution, the ob-
servation that the burden of clinical P. vivax dropped
and continued to decline over the years of intensification
marked a striking difference. Clinical immunity to P.
vivax is acquired rapidly, even under relatively low trans-
mission [15]. In malaria therapy patients, only few mild
febrile symptoms were observed when they were re-
infected with a homologous infection [53]. As relapsing
infections are either genetically identical or meiotic sib-
lings of the primary infection [54, 55], it is generally
thought that clinical episodes are more likely to be
caused by new mosquito-bite-acquired infections. Con-
sidering that reduction in transmission results in the ac-
quisition of fewer new mosquito-derived infections, the
observation that the immediate impact of LLIN was ex-
clusively on incidence of P. vivax clinical episodes and
not on risk of infection strongly suggests that the major-
ity of clinical episodes due to P. vivax may indeed be as-
sociated with mosquito-derived rather than relapsing
infections.
The observation of a delayed impact of LLIN scale-up
on P. vivax compared to P. falciparum blood-stage in-
fections in co-endemic areas is important evidence for
control programmes. It suggests that the large reservoir
of hypnozoites acquired when transmission is high (prior
to scale-up of control) gives rise to a sufficient burden of
relapsing infections that may be transmissible, although
often not symptomatic, such that minimal impact may
be observed on P. vivax prevalence in the years immedi-
ately following scale-up even though transmission is
being reduced. This highlights the importance of
strengthening the implementation of radical cure of P.
vivax in order to accelerate reduction in the burden of
P. vivax [56]. Reluctance to prescribe primaquine with-
out G6PD testing and poor adherence to the 14-day re-
gime are major issues limiting the effectiveness of P.
vivax radical cure in many settings, including PNG.
The observed impact on clinical incidence and the
comparable longer-term reduction in P. vivax and P.
falciparum burden of infections does however provide
reassurance that vector control with LLINs can reduce
the burden of P. vivax, at least in countries where mal-
aria transmission is largely peri-domestic [57], even if
coverage needs to be maintained for a longer period of
time before the full effectiveness is observed. Interest-
ingly, in many countries in Asia and the Americas where
dramatic shifts to P. vivax predominance have been ob-
served, programmes rely upon clinical case management
(often with poor coverage of anti-hypnozoite therapy) as
their primary malaria control strategy [2, 58] and/or
have highly exophilic vectors with transmission occur-
ring mainly in forested areas where LLIN and other
traditional vector control tools such as indoor-residual
spraying have limited efficacy [59–61].
During the period of reduced transmission in 2013,
the individual level of exposure to new blood-stage in-
fections (molFOB) and the geographical location of the
child’s residence were the two key determinants of infec-
tion and illness. In the previous 2006 and 2008 cohorts,
age-dependent decreases in the incidence of clinical P.
vivax were observed [40, 41], suggestive of rapid acquisi-
tion of clinical immunity due to high P. vivax molFOB
during those periods. Conversely, we did not observe
any age association in 2013, which may be explained by
the substantial decline in the force of P. vivax infection.
As documented in other settings, declining transmission
leads to increasing transmission heterogeneity [60, 62] and
an increasing proportion of asymptomatic low-density in-
fections [6–8]. In 2013, over two thirds all PCR-detected in-
fections were sub-microscopic and the risk of clinical
malaria was highly dependent on where the child lived, with
higher risk of clinical illness observed in areas with higher
force of infection. This pronounced spatial heterogeneity in
the risk of infections and malaria illness has also been ob-
served in the two previous cohorts [40–43] indicating that
despite the declining transmission between 2006 and 2013,
the high burden areas remained stable. In particular, we
observed marked geographical clustering of infections and
illness in two areas, Sunuhu 1/2 and Kamanokor/Ilahita 5
in 2013, the same geographical locations that were identi-
fied as highest burden areas before [40, 42, 43] and during
scale-up of interventions [41]. The persistence of high-
burden areas such as these despite the ongoing implemen-
tation of control interventions is supported by observations
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made elsewhere [29, 30] and strengthens the rationale for
surveillance strategies that target interventions to these po-
tential transmission hotspots in order to accelerate control.
Such strategies will clearly need to identify the characteris-
tics of hotspots that fuel sustained transmission and address
the diagnostic challenge imposed by asymptomatic, low-
density infections [5, 63–65].
A limitation of this study is the differences in the study
designs, sampling schedules and the length of follow-up
as well as the non-uniform structuring of the individual
datasets. Consequently, each cohort was analysed separ-
ately and the calculated burden of malaria infection and
disease were compared between the cohorts to deter-
mine the patterns of decline for P. falciparum and P.
vivax across the intervention time-points. As such, we
did not statistically test the differential patterns of de-
cline exhibited by P. falciparum and P. vivax across the
intervention time-points. However, confidence intervals
of the prevalence, molFOB and clinical incidence across
the three cohorts are provided illustrating when differ-
ences are statistically significant. It should also be noted
that the cohorts were conducted in the same study area
with a stable population and the cohorts were age-
matched hence minimising variation between the cohorts.
Lastly, the impact of malaria control interventions on
transmission are a function of diverse social and ecological
settings leading to differences in mosquito abundance, mos-
quito behaviour and human-mosquito interaction. While
improvements in the quality of housing have occurred over
the past decade in many urban areas of PNG, housing for
PNG’s rural majority remains largely dependent on bush
material. Higher quality of housing and socio-economic sta-
tus was associated with reduced risk of malaria in previous
studies in PNG [37]; however, such data is not available
from the child cohorts analysed. The association between
weather patterns and long-term malaria trends in PNG
have also been investigated using site-specific satellite
weather variables and did not explain variations in observed
malaria incidence over time (Rodríguez-Rodríguez &
Hetzel, unpublished data). Further work understanding the
dynamic, complex and responsive ecological niches driving
ongoing malaria transmission in certain areas of PNG will
inform the development of targeted control and elimination
efforts.
Conclusions
Scale-up of standard malaria control interventions in
PNG substantially reduced the burden of malaria infec-
tion and disease in the most vulnerable 1–5-year-old age
group. Data presented here suggests comparable reduc-
tions in new mosquito-derived infections for both P. fal-
ciparum and P. vivax but a delayed impact on P. vivax
relapsing infections due to the previously acquired reser-
voir of hypnozoites. We confirm the effectiveness of
sustained implementation of LLINs and case manage-
ment in reducing transmission of both species in PNG
but highlight the critical need to strengthen case man-
agement, radical cure, surveillance and targeted inter-
vention strategies in order to accelerate control of
malaria in co-endemic settings.
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